Zepbound Psoriatic Arthritis: 1-Year Taltz Combo Results
Zepbound (tirzepatide) is not FDA approved for psoriatic arthritis, but new one-year data from Eli Lilly show it helped when added to Taltz (ixekizumab). In the TOGETHER-PsA trial, released November 11, 2026, 43.7% of adults on Taltz plus Zepbound reached ACR50 (a 50% improvement in arthritis scores) at week 52, compared with 15.7% on Taltz alone, and 85.7% lost at least 10% of their body weight. Everyone in the trial had psoriatic arthritis plus obesity or overweight. If you are losing weight on Zepbound, Sharpy helps you keep muscle with one protein target and one 20-minute workout a day.
Does Zepbound help with psoriatic arthritis? Zepbound (tirzepatide) is not approved for psoriatic arthritis, but in people who have the disease plus obesity or overweight, adding it to Taltz (ixekizumab) worked better than Taltz alone, and the gap grew by one year. On November 11, 2026, Eli Lilly released 52-week results from its TOGETHER-PsA trial. At one year, 43.7% of people on both drugs reached ACR50, compared with 15.7% on Taltz alone. That is close to three times as many.
The data were given as an oral presentation at ACR Convergence 2026, the American College of Rheumatology meeting, and published the same day in Arthritis and Rheumatology. Here is what the numbers mean in plain English.
What is psoriatic arthritis, and why does weight matter?
Psoriatic arthritis (PsA) is an immune disease. It causes swollen, stiff, painful joints, and it often comes with the skin plaques of psoriasis. Taltz treats the immune side by blocking a signal called IL-17A.
Many people with PsA also carry extra weight. Study author Philip Mease, M.D., of Swedish Medical Center in Seattle, said in Lilly's release that reaching meaningful disease control "can be especially challenging" for these patients. The TOGETHER-PsA trial tested a simple idea: treat the joints with Taltz and the weight with Zepbound at the same time.
The Taltz and Zepbound psoriatic arthritis trial
TOGETHER-PsA (NCT06588296) was a 52-week Phase 3b study. It enrolled 271 adults with active psoriatic arthritis and either obesity (BMI of 30 or more) or overweight (BMI of 27 to under 30) with at least one weight-related condition. The average BMI at the start was 37.6.
Half got Taltz alone. Half got Taltz plus Zepbound. Both were injections under the skin, and both groups got advice on eating fewer calories and moving more.
The main goal was strict. A person had to reach both ACR50 and at least 10% weight loss at week 36. ACR50 means a 50% improvement on a standard arthritis score that counts tender and swollen joints, pain and daily function.
Zepbound psoriatic arthritis results at week 36 and week 52
| Result | Week 36: Taltz alone | Week 36: Taltz + Zepbound | Week 52: Taltz alone | Week 52: Taltz + Zepbound |
|---|---|---|---|---|
| ACR50 and 10%+ weight loss (main goal) | 0.8% | 31.7% | 1.7% | 39.2% |
| ACR50 (50% better arthritis score) | 20.4% | 33.5% | 15.7% | 43.7% |
| Lost 10% or more of body weight | 4.5% | 84.5% | 6.7% | 85.7% |
| Minimal disease activity | 15.3% | 26.3% | 13.6% | 28.2% |
Source: Eli Lilly press release, November 11, 2026.
Three things stand out.
The joint benefit grew over time. On the combination, ACR50 rose from 33.5% at week 36 to 43.7% at week 52. On Taltz alone it slipped from 20.4% to 15.7%.
Almost everyone on Zepbound lost real weight. About 86 out of 100 lost 10% or more of their body weight by one year. On Taltz alone, about 7 out of 100 did.
The benefit started early. Lilly said the ACR50 gap opened as early as week 4, before people had lost much weight. That hints tirzepatide may calm inflammation in its own way. It does not prove it.
Does Zepbound help with arthritis pain, fatigue and daily function?
The trial also tracked how people felt and moved. These are average changes from the start of the study to week 52.
| Measure at week 52 | Taltz alone | Taltz + Zepbound | What it measures |
|---|---|---|---|
| DAPSA | -20.3 | -32.2 | Overall PsA disease activity (lower is better) |
| hsCRP | -0.4 mg/L | -2.2 mg/L | A blood marker of inflammation (lower is better) |
| HAQ-DI | -0.3 | -0.6 | Trouble with daily tasks (lower is better) |
| FACIT-Fatigue | +4.8 | +9.7 | Energy level (higher is better) |
Lilly also said blood pressure, blood sugar, HbA1c, triglycerides and total cholesterol improved more with the combination, but it did not give those numbers.
How strong is this evidence?
Read these results with three cautions in mind.
- The week 52 numbers are exploratory. The trial's formal test was at week 36, where the combination beat Taltz alone on the main goal and every key secondary goal. Lilly labels the one-year results as pre-specified but exploratory, without the stricter statistical checks.
- The trial was open label. Patients and doctors knew who got Zepbound. The people scoring the joints did not.
- It did not test Zepbound alone. Everyone took Taltz. So the trial cannot tell you what Zepbound does for psoriatic arthritis without it, or in people at a lower weight.
Is Zepbound approved for psoriatic arthritis?
No. Each drug is approved for its own use:
| Taltz (ixekizumab) | Zepbound (tirzepatide) | |
|---|---|---|
| Approved for psoriatic arthritis | Yes | No |
| Other approved uses | Plaque psoriasis, ankylosing spondylitis, non-radiographic axial spondyloarthritis | Weight management in adults with obesity or overweight plus a weight-related condition; moderate to severe obstructive sleep apnea with obesity |
| How it works | Blocks IL-17A | Activates GIP and GLP-1 receptors |
In practice, a doctor prescribes Taltz for the arthritis and Zepbound for the weight. The November 11 release did not announce any FDA filing for the pair. Never start, stop or change either drug without talking to your prescribers.
Side effects of Taltz and Zepbound together
Lilly said side effects were generally mild to moderate and matched what each drug already shows alone. It did not publish exact rates.
- Taltz plus Zepbound (5% or more of people): nausea, diarrhea, constipation, injection site reactions, vomiting, urinary tract infections, sinusitis, dizziness and headache.
- Taltz alone (5% or more of people): injection site reactions, upper respiratory tract infections, joint pain and diarrhea.
Stomach side effects are the familiar Zepbound pattern. Tell your doctor about severe belly pain, signs of infection or any change in your vision.
Cost: the Taltz and Zepbound savings card
Lilly runs a card called Zepbound Savings for Taltz Patients. When we last checked Lilly's Taltz savings page, on October 25, 2026, eligible people with commercial insurance that covers Taltz could pay as little as $25 a month for the Zepbound pen, and the card was set to end December 31, 2026. Check the page for current terms. Our Zepbound psoriasis guide lists the rules, and our LillyDirect Zepbound guide covers self-pay prices.
Protect your muscle while your joints heal
Losing 10% or more of your weight takes load off sore joints. But some of that loss can be muscle, and muscle is what holds a joint steady. With PsA, that matters twice.
Two habits help most. Eat enough protein every day (our protein target guide shows how to set a number). And do gentle strength work two or three times a week, as your rheumatologist allows (see our resistance training guide).
Sharpy makes this simple. It gives you one protein target, one 20-minute workout and one Shape Score a day, so you can see if you are losing fat and keeping muscle. On a flare day, do less. On a good day, do the full session.
The bottom line
Zepbound is not a psoriatic arthritis drug. But for adults with PsA and extra weight, adding it to Taltz nearly tripled the share reaching ACR50 at one year, and most people lost at least 10% of their weight. The one-year numbers are exploratory, and the pair is not approved as a combination. If both conditions apply to you, ask your rheumatologist whether it makes sense. While you are on Zepbound, Sharpy can help you hold on to muscle. For another joint study, see the retatrutide knee osteoarthritis results.
Sources
- Eli Lilly: New Phase 3b data on Taltz and Zepbound at one year in psoriatic arthritis and obesity (November 11, 2026)
- Merola et al. Ixekizumab With Tirzepatide in Psoriatic Arthritis and Overweight or Obesity. Arthritis and Rheumatology, 2026 (PubMed)
- ClinicalTrials.gov: TOGETHER-PsA, NCT06588296
- Lilly: Taltz savings and support, Zepbound Savings for Taltz Patients
- Lilly: Zepbound prescribing information
Questions people ask
Does Zepbound help with psoriatic arthritis?
It helped when added to Taltz in people who also had obesity or overweight. In the TOGETHER-PsA trial, 33.5% on Taltz plus Zepbound reached ACR50 at week 36 vs 20.4% on Taltz alone. At week 52, it was 43.7% vs 15.7%. There is no large trial of Zepbound alone as a psoriatic arthritis treatment.
Is Zepbound approved for psoriatic arthritis?
No. Zepbound is FDA approved for weight management in adults with obesity, or overweight with a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity. Taltz is the drug approved for active psoriatic arthritis. The November 11, 2026 release from Lilly did not announce any filing for the combination.
Can you take Zepbound with psoriatic arthritis?
Having psoriatic arthritis does not appear as a reason to avoid Zepbound in its label, and TOGETHER-PsA tested it in 271 adults with the disease. Whether it fits you depends on your weight, your other conditions and your other medicines. That is a decision for your rheumatologist and prescriber.
Can a rheumatologist prescribe Zepbound?
Any licensed prescriber can prescribe Zepbound for its approved uses, which are weight management and obstructive sleep apnea with obesity. Some rheumatologists do, and others refer you to primary care or an obesity specialist. Insurance coverage follows the weight or sleep apnea indication, not the arthritis.
Does Zepbound reduce inflammation in psoriatic arthritis?
In TOGETHER-PsA, a blood marker of inflammation called hsCRP fell by 2.2 mg/L at one year on Taltz plus Zepbound vs 0.4 mg/L on Taltz alone. The joint benefit showed up as early as week 4, before much weight was lost. That hints at an effect beyond weight loss, but the trial was not built to prove it.
What are the side effects of Taltz and Zepbound together?
Lilly said side effects were generally mild to moderate and matched what each drug shows alone. The most common on the combination were nausea, diarrhea, constipation, injection site reactions, vomiting, urinary tract infections, sinusitis, dizziness and headache. Lilly did not publish exact rates in its release.